tiprankstipranks
Therma Bright Backs InStatin’s Groundbreaking Respiratory Study
Company Announcements

Therma Bright Backs InStatin’s Groundbreaking Respiratory Study

Story Highlights

Therma Bright (TSE:THRM) has released an update.

Don't Miss our Black Friday Offers:

Therma Bright Inc. has announced its portfolio company InStatin’s new agreement with Mountain West Research to conduct a study aimed at enhancing the delivery of an innovative statin inhalant for asthma and COPD treatment. This research is a significant step towards the development of more effective respiratory therapies and is expected to support upcoming Phase 1 human trials. The company’s investment in InStatin aligns with the growing asthma treatment market, projected to reach USD 39.04 billion by 2032.

For further insights into TSE:THRM stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Canadian Auto-Generated NewsdeskTherma Bright to Spin Off Consumer Products
TipRanks Canadian Auto-Generated NewsdeskTherma Bright’s Strategic Move in Respiratory Solutions
TipRanks Canadian Auto-Generated NewsdeskTherma Bright Partners with U.S. Distributor, Boosts Capital
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App